Shylicine

Vanessa Research Inc. (VRI), located in Hamden, Connecticut, is dedicated to advancing the understanding and treatment of Microvillusinclusion Disease (MVID), a rare genetic disorder that causes severe diarrhea in infants. The company is actively engaged in research and development, focusing on innovative therapies aimed at alleviating life-threatening symptoms associated with this condition.

VRI has developed a patented drug that is set to enter clinical trials, designed to promote normal growth in immature intestinal cells and restore fluid and nutrient absorption. In addition to its research efforts, the company is committed to raising awareness about MVID and supporting families affected by this challenging disease.

Generated from the website